The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TNTY | -81.25% | -94% | -43.03% | -100% |
| S&P | +15.66% | +86.6% | +13.29% | +243% |
Mitesco, Inc. engages in the development, production, and sale of pharmaceuticals. It offers pharmaceutical formulations for both the human and veterinary market. The firm also focuses on the development of software applications in the healthcare arena, including telemedicine, and consideration of services using blockchain encryption technology for various aspects of the healthcare industry. The company was founded on January 18, 2012 and is headquartered in St. Louis Park, MN.
No news articles found for Mitesco.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.00K | -87.2% |
| Gross Profit | -$23.88K | -262.5% |
| Gross Margin | -795.93% | -858.5% |
| Market Cap | $4.09M | 138.3% |
| Market Cap / Employee | $1.36M | 0.0% |
| Employees | 3 | 0.0% |
| Net Income | -$3,202.97K | -254.2% |
| EBITDA | -$1,004.44K | -364.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.32K | -99.0% |
| Accounts Receivable | $36.30K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.37M | 0.0% |
| Short Term Debt | $8.15M | 381.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -3579.58% | -7308.0% |
| Return On Invested Capital | 25.13% | -30.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$120.90K | 20.3% |
| Operating Free Cash Flow | -$120.90K | 20.3% |
| Metric | Q3 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 1.43 | - | |||
| Price to Book | -0.33 | -0.17 | -0.14 | -0.19 | 74.41% |
| Price to Sales | 102.76 | 90.21 | 55.43 | 79.67 | 24.63% |
| Price to Tangible Book Value | -0.33 | -0.17 | -0.14 | -0.18 | 73.38% |
| Enterprise Value to EBITDA | -40.36 | -76.83 | -53.99 | -18.65 | 13.67% |
| Total Debt | $14.43M | $14.29M | $14.40M | $14.51M | 758.30% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
